Recent Advances in Nanotheranostic Agents for Tumor Microenvironment–Responsive Magnetic Resonance Imaging

Longhai Jin¹, Chenyi Yang², Jianqiu Wang¹, Jiannan Li³* and Nannan Xu¹*

¹Department of Radiology, The Second Hospital of Jilin University, Changchun, China, ²Department of Blood Transfusion, Central Hospital of Changchun, Changchun, China, ³Department of General Surgery, The Second Hospital of Jilin University, Changchun, China

Nanomaterials integrating a variety of excellent properties (such as controllable/suitable size, surface modifier, and multifunctionality) have attracted increasing attention in the biomedical field and have been considered a new generation of magnetic resonance imaging (MRI) contrast agents (CAs). In recent years, stimuli-responsive nanomaterials with specifically responsive ability have been synthesized as MRI CAs, which can significantly improve the diagnostic sensitivity and accuracy depending on their outstanding performance. Furthermore, the inherent tumor microenvironment (TME) of malignant tumor is considered to possess several unique features, such as low extracellular pH, redox condition, hypoxia, and high interstitial pressure, that are significantly different from healthy tissues. Hence, constructing nanomaterials for TME-responsive MRI as an emerging strategy is expected to overcome the current obstacles to precise diagnosis. This review focuses on recent advances of nanomaterials in their application of TME-responsive MRI that trigger the diagnostic function in response to various endogenous stimulations, including pH, redox, enzyme, and hypoxia. Moreover, the future challenges and trends in the development of nanomaterials serving as TME-responsive MRI CAs are discussed.

Keywords: nanomaterials, tumor microenvironment, stimuli-responsive, MRI, diagnosis of cancer

INTRODUCTION

Cancer has become a primary cause of death and a most serious threat to human health worldwide (Sung et al., 2021). Early and accurate diagnosis is crucial to conquering cancer, which can guide clinicians to design the most timely, suitable, and reasonable therapeutic strategies for cancer patients. Magnetic resonance imaging (MRI) as one of the most powerful non-invasive imaging instruments with advantages of non-radiation and excellent spatial resolution. It is widely used in the clinical diagnosis of cancer (Na et al., 2009). It can provide anatomical and functional information of organs and soft tissues, for instance, T1 MRI can display normal anatomy with excellent resolution and T2 MRI is adept at detecting tumors and inflammation lesions with outstanding soft tissue imaging. The introduction of contrast agents (CAs) further improves the sensitivity and capability of MRI to detect lesions, which offers unprecedented and comprehensive diagnostic information for clinicians (Lohrke et al., 2016). Gadolinium (Gd³⁺) chelate–based MRI CAs are most commonly used in clinics at present. However, these Gd-based CAs have their own limitations, such as very short...
internal circulation time, poor specificity, and relatively low relaxation efficiency. In order to overcome the above defects, it is necessary to use large doses of Gd-based CAs to increase the CA concentration in the target area (Raymond and Pierre, 2005). Afterward, high-dose injection of Gd³⁺ chelates may cause severe nephrogenic systemic fibrosis syndrome, as has been warned by the US Food and Drug Administration (FDA) (Penfield and Reilly, 2007; Perez-Rodriguez et al., 2009; Chen et al., 2012). Therefore, the comprehensive performance of currently available CAs in clinic is far from ideal. Research and development of innovative and efficient MRI CAs as a substitute for traditional Gd-based CAs is highly desirable and has become a very promising field.

Over the past decades, nanomaterials integrating a variety of excellent properties have been proposed as a new generation of CAs with great potential in MRI. As imaging CAs, nanomaterials have a series of attractive characteristics: 1) controllable and suitable size, which ensures sufficient circulation time in blood and clearance ability by kidneys or reticuloendothelial system (RES) (Longmire et al., 2011). 2) Surface modifiers, which allow them to be coated with biocompatible materials to improve their biocompatibility or conjugated with ligands to provide additional properties such as target-specific binding ability, barrier-penetrating ability, and long circulation time (Lim et al., 2015). 3) Multifunctionality, integrating multiple imaging modes into one platform, making them capable of providing comprehensive information for detecting lesions. The most frequently developed nanomaterials as T1 MRI CAs are Gd-based complexes (e.g., Gd₂O₃⁻, NaGdF₄⁻, GdF₃⁻, and Gd³⁺-doped nanoparticles [NPs]) (Liu et al., 2011; Kimura et al., 2012; Park et al., 2012; Passuello et al., 2012; Xing et al., 2014; Du et al., 2017) and paramagnetic manganese (Mn)-based composites (e.g., MnO NPs, MnO₂ nanosheets, and Mn₃O₄ NPs) (Kim et al., 2011; Chen et al., 2014; Li et al., 2017), which can shorten their longitudinal relaxation time (T₁) due to their excellent ability to interact with hydrogen protons in the surrounding water. Superparamagnetic iron oxide (SPIO) NPs are the other kind of popular CAs which can shorten transverse relaxation time (T₂) because of their intrinsic magnetic properties, serving as T₂ MRI CAs (Laurent et al., 2008; Tong et al., 2010). Despite the variety of nanomaterials with remarkable performance having been synthesized as MRI CAs which undeniably improved the sensitivity of detecting subtle lesions to a certain extent, there are still some shortcomings that cannot be neglected. For instance, 1) the majority of current MRI CAs cannot possess the function of enhancing MR contrast signals "always on" regardless of their specific accumulation in target tumors or tissues, leading to poor target-to-background signal ratios. Therefore, it is difficult to distinguish the region of interest from surrounding normal tissues due to non-specific signal enhancement, which may lead to a false-positive diagnosis or missed diagnosis (Yoo and Pagel, 2008; Fu et al., 2021). 2) Dissatisfactory relaxivity causes insufficient sensitivity to detect early-stage tumors or tiny lesions, which may miss the optimal opportunity for treatment (Yu et al., 2014; Lee et al., 2015). 3) Inadequate internal circulation time results in narrow observation window of MRI, reduces diagnostic efficiency, and impedes their applications (Kielar et al., 2010; Ai, 2011; Shen et al., 2017).

Consequently, designing stimuli-responsive CAs with specifically responsive ability is expected to overcome the above obstacles. Compared with traditional CAs, these stimuli-responsive CAs have exhibited conspicuously enhanced contrasts between target lesions (especially the small lesions or early-stage tumors) and normal tissues. Many endogenous or exogenous stimuli have been exploited to serve as triggers for stimuli-responsive CAs previously, including endo-stimuli (internal) such as pH, redox, and enzymes, and exo-stimuli (external) such as light, temperature, ultrasound, and electric or magnetic fields (Kang et al., 2017; García-Hevia et al., 2019). In addition, the tumor microenvironment (TME) of various types of malignant tumors, affected by malignant proliferation and metabolism, is considered to possess several unique features such as low extracellular pH, redox conditions, hypoxia, and high interstitial pressure (Danhier et al., 2010; Joyce and Fearon, 2015; Zhu et al., 2022). Nanomaterial-based TME-responsive CAs have attracted widespread attention for personalized cancer diagnosis owing to their outstanding performances in tumor-specific imaging, which could provide more accurate information for precise diagnosis of cancer and optimize treatment strategies (Yang et al., 2018; Wang J. et al., 2021).

This review aims to summarize the recent advances and future prospects of nanomaterial-based CAs in their TME-responsive MRI applications rather than attempting to thoroughly contain the whole field (Figure 1). The inherent TME properties of tumors are significantly different from healthy normal tissues, which have been utilized in developing stimuli-responsive nanomaterial-based CAs for tumor-specific imaging. In this review, TME-responsive MRI CAs are classified according to types of

FIGURE 1 | General strategies to synthesize nanotheranostic agents for TME-responsive MRI.
endogenous stimulation, including pH, redox, enzyme, and hypoxia.

**PH-RESPONSIVE MRI CONTRAST AGENTS**

According to the Warburg effect, abnormal and rapid proliferation of tumor cells consumes a lot of oxygen and nutrients, leading to acidosis and a reduced pH in the neighboring microenvironment (Vaupel et al., 1989; Webb et al., 2011). Thus, the extracellular pH values in TME are typically acidic in many tumors, differing significantly from those of normal tissues and blood (Lee et al., 2007). The pH-responsive MRI CAs provide noninvasive contrast enhancement depending on pH, which could be applied to tumor-specific imaging. General designs of pH-responsive MRI CAs can be classified by imaging components.

**Gd-Based pH-Responsive MRI CAs**

Gd chelate is the most commonly used commercial MRI CA, so Gd-based pH-responsive MRI CAs have been widely studied. Zhu et al. attached pH-responsive block polymers on the surface of Gd-based NPs to achieve a surface modified Gd-metal organic frame (MOF) structure as a pH-responsive CA for MRI, which exhibited good performance in a series of characterization tests as well as imaging tests (Zhu et al., 2016). Its longitudinal relaxivity ($R_1$) changed with the variation of environmental pH. The $R_1$ value ranged from 6.6 mM$^{-1}$s$^{-1}$ at pH 7.3 to 11.7 mM$^{-1}$s$^{-1}$ at pH 6.6. To improve the biocompatibility and biodegradability of CAs, silkworm sericin (SS) was used to cross-link with Gd-based NPs by Huang et al. (Huang et al., 2021). A pH-responsive Gd-based NPs SS@GAH-GdCl$_3$ with $R_1$ values as 16.4 mM$^{-1}$s$^{-1}$ at pH 5.8 and 9.2 mM$^{-1}$s$^{-1}$ at pH 7.4 was obtained that showed a certain degree of increase with the decrease of pH value.

**Fe-Based pH-Responsive MRI CAs**

Fe is another essential element in the human body, mainly existing as ferritin in blood circulation. Paramagnetic Fe$^{3+}$ is regarded as a promising candidate as T1 MR CAs owing to its large number of unpaired electrons (Wu et al., 2014; Zhang et al., 2017). Qu et al. recently fabricated an Fe-based biomimetic melanin-like multifunctional nanoagent (amino-Fe-PDANPs) as a positive pH-responsive MRI CA (Qu et al., 2021). Polydopamine was employed as a pH-responsive sensitizer for imaging. The $R_1$ value was 10.0 mM$^{-1}$s$^{-1}$ at pH 7.5, then increasing to 15.4 mM$^{-1}$s$^{-1}$ at pH 6.5. It has been proven that the approachability of water molecules to the paramagnetic centers is the critical factor for T1 signal enhancement (Taylor et al., 2008). Interestingly, Fe-based NPs are also extensively applied as T2 MR CAs. Their magnetic property reduces rapidly with decreasing size owing to the reduction of magnetic anisotropy and spin disordering on the surface of NPs (Jun et al., 2008). Liu et al. synthesized PEGylated ultrasmall superparamagnetic iron oxide nanoparticles (USPIONs) by incorporating the methods of microemulsion and biominalization, and coating with CaCO$_3$ to obtain PEG-USPIONs@CaCO$_3$ as a pH-responsive T2-T1-switchable MRI CA (Liu et al., 2021). The USPIONs agglomerated compactly inside the nanostructure, resulting in the enhancement of the T2 signal. While exposed to the acidic conditions in the tumor microenvironment, the CaCO$_3$-layer releases free USPIONs by degradation, then switching to T1 MRI signal enhancement. With the gradual decrease of pH value, the $R_2/R_1$ ratio reduces substantially. In brief, PEG-USPIONs@CaCO$_3$ will change from T2 CA in the neutral pH condition to T1 CA in the acidic environment of tumors. Not coincidentally, He et al. reported an extremely small iron oxide nanoparticle (ESIONP)-based pH-responsive T1-T2-switchable MRI CA which exhibited good performance (He et al., 2020).
**REDOX-RESPONSIVE MRI CONTRAST AGENTS**

In addition to weakly acidic pH, redox state as another characteristic biomarker of TME has drawn remarkable attention. Glutathione (GSH), among a variety of redox couples, is usually considered the most important thiol-disulfide redox buffer in charge of maintaining the balance of intracellular redox reactions (Do et al., 2014; Zhao et al., 2022). The concentration of GSH in tumor cells is much higher than that in normal tissues or blood (Cheng et al., 2011). Therefore, reduction-sensitive disulfide bonds and hydrogen peroxide (H₂O₂)–responsive boronated moieties were extensively used as redox-responsive MRI CAs. While Gd itself cannot be reduced, many other metal ions have been developed, such as Mn, Fe, Co, Eü, and Cu.

**Mn-Based Redox-Responsive MRI CAs**

Recently, Wang et al. developed an intelligent redox-responsive nanoplatform (MUM NPs) via the coprecipitation process involving upconversion NPs (UCNPs) and aggregation-induced emission-active photosensitizers, as well as an in situ generation process of MnO₂ as the outer shell (Wang Y. et al., 2021). MUM NPs exhibited high specificity to TME, rapidly exhausting intracellular GSH and efficiently generating Mn²⁺, which were instrumental in ROS preservation and T₁ MRI enhancement, respectively. This nanoplatform performed well in redox-responsive MR imaging. In addition to single-mode stimuli-responsive MRI, Kim et al. designed a redox-responsive T₁/T₂ dual-mode MRI CA, integrating a superparamagnetic core (FeO₂) and a paramagnetic shell (MnO₂) into a core-shell structure through a seed-mediated growth process (Kim et al., 2016). Under the stimulation of tumor’s intracellular reducing environments by glutathione, the MnO₂ shell will be decomposed into Mn²⁺ for T₁ signal enhancement and allow FeO₂ to interact with water protons for T₂ signal enhancement. Under GSH-free conditions, the r₁ was 2.4 mM⁻¹s⁻¹ and the r₂ was 92.2 mM⁻¹s⁻¹. After activation in GSH solution, the r₁ and r₂ values increased to 16.1 and 258.6 mM⁻¹s⁻¹, illustrating that this nanoplatform can be qualified as redox-responsive T₁/T₂ dual-MRI CA.

**Fe-Based Redox-Responsive MRI CAs**

The yolk-shell type of GSH-responsive nanovesicles (NVs) were synthesized to encapsulate USPIO NPs and chemotherapy drugs by Liu et al.; the obtained USD NVs can respond to GSH-releasing drugs and activate T₁ signal enhancement (Liu et al., 2020). The r₁ value increased obviously to 3.1 mM⁻¹s⁻¹ in the presence of GSH. For switchable MRI, Cao et al. encapsulated citric acid–modified ESIONPs-Cₐ in disulfide cross-linked poly (CBMA) nanogels, further introducing tumor-targeted c (RGD) ligand to obtain ICNs-RGD (Cao et al., 2020). With the stimulation of GSH, ICNs-RGD are rapidly degraded, and the agglomerated ESIONPs are dispersed evenly, which achieves switching from a T₂ CA to a T₁ one. ICNs-RGD exhibits a T₂ contrast effect (dark) during its transport in the vessel, then switches to a T₁ contrast effect (bright) after reaching the tumor region with a redox microenvironment. After stimulation by GSH, the r₁ value was increased mildly from 5.56 to 7.40 mM⁻¹s⁻¹ and the r₂ value drastically decreased from 103.01 to 14.36 mM⁻¹s⁻¹, which demonstrated that ICNs-RGD had the potential to be an efficient MRI CA in clinics.

**ENZYME-RESPONSIVE MRI CONTRAST AGENTS**

Because of their unique substrate specificity and high selectivity as well as efficient catalysis in biochemical reactions, enzymes play an indispensable role in most biological and metabolic processes, which can be associated with a series of pathological changes, such as tumors, inflammation, and so on (Zhang et al., 2014; Wang et al., 2019). In particular, cathepsin B and matrix metalloproteinases (MMPs) with elevated expression in the tumor environment participate in numerous biological processes associated with cancer, such as progression, metastasis, and angiogenesis. These tumor-associated enzymes can be regarded as stimulators for enzyme-responsive imaging or treatment of cancer (Hu et al., 2012). By means of one step reaction, Sun et al. synthesized hyperbranched poly (oligo-(ethylene glycol) methacrylate)-Gd complexes (HB-POEGMA-Gd and HB-POEGMA-cRGD-Gd), which employed lysosomal cathepsin B as a stimuli-response component to realize enzyme-responsive T₁ CA (Sun et al., 2016). Their r₁ values were 12.25 and 14.65 mM⁻¹s⁻¹, respectively. Recently, Yan et al. reported a Gd-based enzyme-responsive MRI and NIR fluorescence imaging CA (P-CyFF-Gd) with alkaline phosphatase (ALP) as a model enzyme (Yan et al., 2019). Upon ALP activation, r₁ increased from 8.9 to 20.1 mM⁻¹s⁻¹, which demonstrated that P-CyFF-Gd can be qualified as a new generation of enzyme-responsive T₁ CA. Another Gd-based enzyme-responsive T₁ CA was designed through a self-assembly approach with caspase-3/7 as an activator by Ye et al. (Ye et al., 2014). The r₁ value significantly increased from 10.2 mM⁻¹s⁻¹ before activation to 19.0 mM⁻¹s⁻¹ after activation. For enzyme-responsive T₂ imaging, Gallo et al. constructed Fe-based MMP, enzyme-activatable, and tumor-specific targeting NPs, which were tethered with CXCR4-targeted peptide ligands for targeting tumors (Gallo et al., 2014). Upon MMP activation, the structure of NPs changes to that of a self-assembled superparamagnetic cluster network through a cyclodaddition reaction, resulting in T₂ signal enhancement.

**HYPOXIA-RESPONSIVE MRI CONTRAST AGENTS**

The malignant proliferation of tumors depletes a large amount of oxygen, resulting in the hypoxia of the tumor environment. As an inevitable feature of tumors, hypoxia is considered to be the obvious causative factor of therapeutic resistance and metastasis (Gatenby and Gillies, 2008). Therefore, exploiting novel nanotheranostics to achieve accurate diagnosis of hypoxia and timely treatment simultaneously has drawn great attention in biomedical research as well as clinical studies. The Gd complex of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid with a 2-nitroimidazole attached to one carboxyl group by an amide linkage was synthesized by Rojas-Quijano et al.; the r₁ value was determined to be 6.38 mM⁻¹s⁻¹. The MR imaging results demonstrated that the nitroimidazole-derivat modified nanoprobe could be qualified as a hypoxia-responsive T₁ CA.
to distinguish hypoxic from normoxic tissues. For Mn-based CAs, Song et al. constructed a rattle-structured NP consisting of a UCNP core, a hollow mesoporous silica shell, and hypoxia-sensitive MnO2 nanosheet modification (Song et al., 2018). MnO2 could be disintegrated into Mn2+ to achieve hypoxia-responsive T1 signal enhancement, and the r1 value is 1.137 mM$^{-1}$s$^{-1}$ after activation.

Neill et al. studied the possibility of Co-based bioreductive prodrugs working as a hypoxia-responsive MRI CA. Once in the hypoxic environment of tumors, the diamagnetic Co(III) ions of the CA will be reduced to ions of paramagnetic Co(II), ones which could significantly shorten the T2 relaxation to realize a T2 signal enhancement.

**DISCUSSION**

TME-responsive MRI CAs have been widely developed for accurate diagnosis of cancer because of their outstanding properties. The recent work on nanomaterials for TME-responsive MRI is summarized in Table 1. Although great efforts have been devoted to exploring a variety of TME-responsive MRI CAs in the biomedical field, there are still some problems that need to be solved for accelerating their clinical transformation. 1) Up to date, most studies of stimuli-responsive CAs based on nanomaterials stay in the stage of concept verification as well as the research of laboratory application; systematic and in-depth researches are needed to promote their clinical application. 2) The safety concerns of these CAs need to be investigated more thoroughly, including their long-term biocompatibility, pharmacokinetics, biodistribution, biodegradability, and excretion, which are vitally important for their clinical transformation. 3) Despite numerous stimuli-responsive CAs exhibiting good performance, nanomaterials with better properties (such as high relaxivity, adequate circulation time, and appropriate stimuli-response function) should be explored to further improve the imaging effect and diagnostic efficiency. We believe that ingenious design and construction of TME-responsive MRI CAs will greatly promote the development of early and accurate cancer diagnosis in the future.

**AUTHOR CONTRIBUTIONS**

JL and NX conceived the topic and structure of the article. LJ conducted the literature research and drafted the manuscript. CY and JW prepared the figures, tables, and manuscript amendments. JL and NX reviewed and refined the manuscript.

**FUNDING**

This work was supported by the National Natural Science Foundation of China (Grant No. 32000953), the Natural Science Foundation of Jilin Province (Grant No. 20210101287[C]), the Financial Department of Jilin Province (Grant No. 2019SCZT045), the Fundamental Research Funds for the Central Universities (Grant No. 415010200060), and the Education Project of Jilin University (#419070600046 and 45121031D024).

**TABLE 1** | Summary of recent work on nanomaterials for TME-responsive MRI.

| Nanomaterial | Responsive | Imaging component | Imaging mode | Relaxivity | References |
|--------------|------------|-------------------|--------------|------------|------------|
|              |            |                   | Before activation | After activation |
| GdNPs        | pH         | Gd                | T1           | r1 = 8.3   | r1 = 11.7  | Zhu et al. (2016) |
| Gd-PCNPs     | pH         | Gd                | T1           | r1 = 6.62  | r1 = 10.01 | Jiang et al. (2017) |
| SS@GdCl3     | pH         | Gd                | T1           | r1 = 9.2   | r1 = 16.4  | Huang et al. (2021) |
| HMCNs        | pH         | Mn                | T1           | r1 = 0.79  | r1 = 8.81  | Chen et al. (2012) |
| Mn-LDH       | pH         | Mn                | T1           | r1 = 1.16  | r1 = 9.48  | Li et al. (2017) |
| Co-P@SiO₂@DOX-MnO₂ | pH, Mn, Co | T1, T2          | r1 = 9.05   |            | Li et al. (2017) |
| Amino-Fe-PDANPs | pH   | Fe                | T1           | r1 = 10.0  | r1 = 15.4  | Qu et al. (2021) |
| ESIONP system| pH         | Fe                | T1 to T2     | r1 = 5.71  | r1 = 3.88  | He et al. (2020) |
| PEG-USPIONs @CaCO₃ | pH | Fe                | T2 to T1     | r2 = 9.11  | r2 = 42.2  | Liu et al. (2021) |
| MUM NPs      | Redox      | Mn                | T1           | r1 = 0.12  | r1 = 6.89  | Wang et al. (2021b) |
| RANS         | Redox      | Mn                | T1, T2       | r1 = 2.4   | r1 = 16.1  | Kim et al. (2016) |
| USD NPs      | Redox      | Fe                | T1           | r2 = 92.2  | r2 = 258.6 | Liu et al. (2020) |
| HIONPs       | Redox      | Fe                | T1, T2       | r1 = 41.3  | r2 = 118.7 |
| ICNs-RGD     | Redox      | Fe                | T2 to T1     | r1 = 5.56  | r1 = 7.4   | Cao et al. (2020) |
| P-CyFF-Gd    | Enzyme     | Gd                | T1           | r1 = 8.9   | r1 = 20.1  | Yan et al. (2019) |
| HB-POEGMA-rGD-Gd | Enzyme | Gd                | T1           | r1 = 10.2  | r1 = 19.0  | Ye et al. (2014) |
| C-SNAM       | Enzyme     | Gd                | T1           | r2 = 3.1   |            | Gallo et al. (2014) |
| IONPs        | Enzyme     | Fe                | T2           |            |            | Rojas-Quijano et al. (2012) |
| Gd-complexes | Hypoxia    | Gd                | T1           | r1 = 6.38  |            | Song et al. (2018) |
| DOX-UCHSM-PEG-DOTA | Hypoxia | Mn                | T1           | r1 = 0.112 | r1 = 1.137 | O’Neill et al. (2017) |
| CoTPA complexes | Hypoxia     | Co                | T2           |            |            |
Inductively Coupled Plasma Mass Spectrometry and Magnetic Resonance Imaging Studies. *Inorg. Chem.* 56 (16), 9860–9868. doi:10.1021/acs.inorgchem.7b03368

Park, Y. I., Kim, H. M., Kim, J. H., Moon, K. C., Yoo, B., Lee, K. T., et al. (2012). Theranostic Probe Based on Lanthanide-Doped Nanoparticles for Simultaneous *In Vivo* Dual-Modal Imaging and Photodynamic Therapy. *Adv. Mater.* 24 (42), 5755–5761. doi:10.1002/adma.201202433

Passuello, T., Pedroni, M., Piccinelli, F., Polizzi, S., Marzola, P., Tambalo, S., et al. (2012). PEG-capped, Lanthanide Doped GdF3 Nanoparticles: Luminescence and T2 Contrast Agents for Optical and MRI Multimodal Imaging. *Nanoscale* 4 (24), 7682–7689. doi:10.1039/c2nr31796f

Penfield, J. G., and Reilly, R. F., Jr. (2007). What Nephrologists Need to Know about Gadolinium. *Nat. Clin. Pract. Nephrol.* 3 (12), 654–666. doi:10.1038/neph06660

Perez-Rodriguez, J., Lai, S., Ehst, B. D., Fine, D. M., and Bluemke, D. A. (2009). Nephrogenic Systemic Fibrosis: Incidence, Associations, and Effect of Risk Factor Assessment-Report of 33 Cases. *Radiology* 250 (2), 371–377. doi:10.1148/radiol.2502080498

Qu, J., Guilloy, D., Cheah, P., Tian, B., Zheng, J., Liu, Y., et al. (2021). Synthesis of Biomimetic Melanin-like Multifunctional Nanoparticles for pH Responsive Magnetic Resonance Imaging and Photothermal Therapy. *Nanomater. (Basel)* 11 (8), 03390. doi:10.3390/nano11082107

Raymond, K. N., and Pierre, V. C. (2005). Next Generation, High Relaxivity Inorg. Chem. Studies. Inductively Coupled Plasma Mass Spectrometry and Magnetic Resonance Imaging Features at Gadoxetic Acid-Enhanced MR Imaging. *Radiology* 271 (3), 748–760. doi:10.1148/radiol.2713111996

Ye, D., Shuhendler, A. J., Pandit, P., Brewer, K. D., Tee, S. S., Cui, L., et al. (2014). Caspase-responsive Smart Gadolinium-Based Contrast Agent for Magnetic Resonance Imaging of Drug-Induced Apoptosis. *Chem. Sci.* 4 (10), 3845–3852. doi:10.1039/C3SC6392A

Yoo, B., and Pagel, M. D. (2008). An Overview of Responsive MRI Contrast Agents for Molecular Imaging. *Front. Biosci.* 13, 1733–1752. doi:10.2741/2796

Zhang, H., Li, L., Liu, X. L., Jiao, J., Ng, C. T., Yi, J. B., et al. (2017). Ultrasmall Ferrite Nanoparticles Synthesized via Dynamic Simultaneous Thermal Decomposition for High-Performance and Multifunctional T1 Magnetic Resonance Imaging Contrast Agent. *Nano Lett.* 17 (4), 3614–3631. doi:10.1021/acs.nanolett.6b07684

Zhao, T., Wu, M., Liu, M., Han, L., Wang, S., Liu, S., Yang, Y., et al. (2022). Rheumatoid Arthritis Microenvironment Insights into Treatment Effect of Nanomaterials. *Nano Today* 42, 101358. doi:10.1016/j.nantod.2021.101358

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Jin, Yang, Wang, Li and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.